XBiotech (NASDAQ:XBIT) (NASDAQ: XBIT) is a clinical‐stage biotechnology company focused on the discovery, development and commercialization of true human monoclonal antibody therapies. Leveraging proprietary antibody isolation and manufacturing platforms, the company’s primary mission is to develop treatments that neutralize disease-causing proteins implicated in a range of inflammatory, cardiovascular, dermatological and oncological conditions. XBiotech operates as a vertically integrated organization, overseeing all stages from early research and development to clinical trials, regulatory submissions and potential commercialization.
The company’s lead candidate, bermekimab, is a true human monoclonal antibody designed to target interleukin‐1 alpha (IL-1α), a pro-inflammatory cytokine involved in a variety of disease processes. Bermekimab has advanced through multiple clinical programs, including pivotal studies in conditions such as colorectal cancer–associated cachexia, hidradenitis suppurativa and atherosclerotic vascular disease. In parallel, XBiotech is exploring additional candidates for indications in oncology and autoimmune diseases, collaborating with academic centers and contract research organizations across North America, Europe and Asia to conduct global clinical trials. The company’s integrated manufacturing capacity supports scalable production, positioning XBiotech to supply commercial quantities pending regulatory approval.
Founded in 2008 and headquartered in Austin, Texas, XBiotech was established with the vision of harnessing naturally occurring human antibodies to create safer, more effective therapies. The company was co‐founded by Dr. Stephen Jesse and maintains research facilities in the United States, with strategic partnerships that extend its reach into European and Asian markets for clinical development. Leadership is headed by Chief Executive Officer John Simard, whose background in biotech operations and commercial strategy guides XBiotech’s development and potential launch plans. The executive team includes seasoned professionals in clinical research, regulatory affairs and manufacturing.
Looking ahead, XBiotech aims to advance bermekimab through late‐stage clinical trials and to expand its pipeline of true human antibodies targeting novel disease pathways. The company continues to engage in strategic collaborations to bolster its clinical development programs and to secure partnerships for potential co‐development or licensing. With a commitment to innovative antibody science, XBiotech seeks to address unmet medical needs and deliver new therapeutic options for patients worldwide.
